Stryker (NYSE:SYK) Issues FY 2026 Earnings Guidance

Stryker (NYSE:SYK) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 14.900-15.100 for the period, compared to the consensus EPS estimate of 14.960. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent research reports. Barclays increased their target price on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. UBS Group set a $408.00 target price on Stryker in a research report on Monday, October 13th. Evercore ISI set a $390.00 price objective on shares of Stryker in a report on Monday, January 5th. Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a research note on Tuesday, January 6th. Finally, Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price target on the stock in a research report on Friday, December 19th. Twelve analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $425.94.

Stryker Stock Performance

NYSE:SYK opened at $354.39 on Friday. The business’s fifty day moving average is $359.38 and its 200 day moving average is $371.95. The firm has a market cap of $135.52 billion, a price-to-earnings ratio of 46.57, a PEG ratio of 2.29 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. Stryker has a 52-week low of $329.16 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The company’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the business posted $4.01 earnings per share. Research analysts predict that Stryker will post 13.47 EPS for the current year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s dividend payout ratio is presently 46.25%.

Insider Buying and Selling at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the sale, the chief accounting officer owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 522,118 shares of company stock worth $185,381,932 over the last three months. Company insiders own 5.90% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat — Stryker posted Q4 adjusted EPS $4.47 (vs. $4.40 consensus) and revenue $7.17B, with organic sales up ~11% and adjusted operating margin expanding 100 bps, signaling continued top‑line momentum and operating leverage. Stryker reports 2025 operating results and 2026 outlook
• Positive Sentiment: Raised outlook/supportive commentary — Management now guides 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS $14.90–$15.10 and indicated modestly favorable pricing and FX, prompting firms to keep/confirm Buy ratings. Reuters notes management raised its profit forecast tied to strong capital and implant demand. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analyst support — Multiple shops (Needham, Piper Sandler and others) reiterated Buy/Overweight ratings after the results, citing sustained double‑digit growth in key MedSurg/Neuro businesses and improved margins. Stryker: Sustained Double-Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: FY26 EPS range roughly in line with consensus — the $14.90–$15.10 range centers near Street estimates (consensus ~14.96). That calmingly conservative guidance reduces upside surprise potential and helps explain muted share reaction despite the beat.
• Neutral Sentiment: Earnings call / details available — full Q4 earnings call transcript and company presentation provide more color on product momentum, capital demand and margin drivers for investors reviewing catalysts. Stryker Q4 2025 Earnings Call Transcript
• Negative Sentiment: Tariff/regulatory risks flagged — some analysts and the company note potential 2026 tariff headwinds and geopolitical/regulatory risks that could pressure margins or growth in certain markets if they materialize.
• Negative Sentiment: Large insider selling noted by data providers — recent public filings and data aggregators show substantial insider share sales over the past 6 months, which can amplify sell‑side pressure or signal near‑term positioning changes. QuiverQuant summary & insider activity
• Negative Sentiment: Product/segment items — notable declines or one‑time items (e.g., a material drop in spinal implants year/quarter comparisons and earlier goodwill/impairment charges) remain on the P&L and are potential longer‑term headwinds for parts of Orthopaedics. Stryker reports 2025 operating results and 2026 outlook

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SYK. United Financial Planning Group LLC bought a new position in Stryker in the third quarter worth about $27,000. Strive Asset Management LLC purchased a new position in shares of Stryker in the 3rd quarter valued at approximately $30,000. Wiser Advisor Group LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $61,000. Quarry LP bought a new position in Stryker in the third quarter worth $63,000. Finally, Binnacle Investments Inc boosted its holdings in shares of Stryker by 26.1% during the 2nd quarter. Binnacle Investments Inc now owns 179 shares of the medical technology company’s stock valued at $71,000 after buying an additional 37 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.